

Myron S Cohen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/439304/myron-s-cohen-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

14,989
citations

46
h-index

113
g-index

113
ext. papers

17,713
ext. citations

13.7
avg, IF

5.74
L-index

#	Paper	IF	Citations
106	Experimental Urethral Infection with <i>Neisseria gonorrhoeae</i> .. <i>Current Topics in Microbiology and Immunology</i> , 2022 , 1	3.3	0
105	Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis.. <i>Lancet HIV,the</i> , 2022 , 9, e254-e268	7.8	5
104	A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.. <i>Science Translational Medicine</i> , 2021 , 14, eabl7430	17.5	48
103	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. <i>Cell Reports</i> , 2021 , 37, 109922	10.6	1
102	Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	2
101	Evaluation of Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052. <i>Clinical Infectious Diseases</i> , 2021 , 72, 30-37	11.6	6
100	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021 , 384, 1003-1014	59.2	77
99	A randomized controlled trial evaluating combination detection of HIV in Malawian sexually transmitted infections clinics. <i>Journal of the International AIDS Society</i> , 2021 , 24, e25701	5.4	1
98	Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1717-1721	11.6	8
97	Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates 2021 ,		1
96	Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052. <i>International Journal of STD and AIDS</i> , 2021 , 32, 1204-1211	1.4	
95	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021 , 64, 103203	8.8	7
94	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1581-1592	7	13
93	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. <i>Scientific Reports</i> , 2021 , 11, 15531	4.9	20
92	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021 , 385, 595-608	59.2	48
91	SARS-CoV-2 Variants in Patients with Immunosuppression. <i>New England Journal of Medicine</i> , 2021 , 385, 562-566	59.2	92
90	Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1670-1680	7	3

89	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020 , 181, 189-206	56.2	48
88	Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. <i>Frontiers in Immunology</i> , 2020 , 11, 156	8.4	5
87	Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. <i>New England Journal of Medicine</i> , 2020 , 383, e63	59.2	46
86	Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda. <i>Lancet HIV,the</i> , 2020 , 7, e173-e183	7.8	26
85	Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. <i>Lancet HIV,the</i> , 2020 , 7, e721-e730	7.8	10
84	Identifying Regions of Greatest Need for Ending the HIV Epidemic: A Plan for America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 395-398	3.1	1
83	Variations in HIV Risk by Young Women's Age and Partner Age Disparity in Rural South Africa (HPTN 068). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 350-356	3.1	6
82	Covid-19, Ebola, and HIV - Leveraging Lessons to Maximize Impact. <i>New England Journal of Medicine</i> , 2020 , 383, e106	59.2	9
81	Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 821-830	6.1	6
80	Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. <i>Journal of the International AIDS Society</i> , 2019 , 22 Suppl 6, e25355	5.4	28
79	Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25419	5.4	24
78	Phylogenetic Methods Inconsistently Predict the Direction of HIV Transmission Among Heterosexual Pairs in the HPTN 052 Cohort. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1406-1413	7	13
77	Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. <i>Antiviral Therapy</i> , 2019 , 24, 45-50	1.6	3
76	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 484-491	3.1	5
75	Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 350-357	3.1	3
74	Ethical considerations in global HIV phylogenetic research. <i>Lancet HIV,the</i> , 2018 , 5, e656-e666	7.8	22
73	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , 2018 , 9, 1928	17.4	46
72	Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 867-878	1.6	3

71	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017 , 2,	28	86
70	Virion incorporation of integrin $\alpha 7$ facilitates HIV-1 infection and intestinal homing. <i>Science Immunology</i> , 2017 , 2,	28	34
69	Virologic outcomes in early antiretroviral treatment: HPTN 052. <i>HIV Clinical Trials</i> , 2017 , 18, 100-109		18
68	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	127
67	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	59
66	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21579	5.4	72
65	Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, 112-116	3.1	46
64	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017 , 9,	0.7	50
63	Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. <i>PLoS ONE</i> , 2017 , 12, e0177281	3.7	2
62	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2016 , 375, 830-9	59.2	889
61	Antiretroviral Therapy to Prevent HIV Acquisition: Limits of Estimation From a Population Cohort. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1679-1680	11.6	2
60	Let's treat everyone with HIV now: what happens next?. <i>Lancet HIV</i> , 2016 , 3, e109-10	7.8	
59	Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China, 2006 to 2012. <i>Clinical Infectious Diseases</i> , 2015 , 61, 111-9	11.6	17
58	R5 Macrophage-Tropic HIV-1 in the Male Genital Tract. <i>Journal of Virology</i> , 2015 , 89, 10688-92	6.6	7
57	How can we better identify early HIV infections?. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 61-8	4.2	49
56	Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6395-401	5.9	4
55	Phenotypic Correlates of HIV-1 Macrophage Tropism. <i>Journal of Virology</i> , 2015 , 89, 11294-311	6.6	40
54	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015 , 18, 354-62	23.4	53

53	Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 69, 234-40	3.1	48
52	Injectable Progestin-Only Contraception is Associated With Increased Levels of Pro-Inflammatory Cytokines in the Female Genital Tract. <i>American Journal of Reproductive Immunology</i> , 2015 , 74, 357-67	3.8	55
51	Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. <i>Nature Reviews Microbiology</i> , 2015 , 13, 414-25	22.2	120
50	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015 , 161, 1280-92	56.2	219
49	A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. <i>BMC Infectious Diseases</i> , 2015 , 15, 479	4	67
48	Ongoing HIV Transmission and the HIV Care Continuum in North Carolina. <i>PLoS ONE</i> , 2015 , 10, e0127950	3.7	23
47	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 281-90	25.5	345
46	Oral Maraviroc and Tenofovir for HIV Prevention in Women: An Ex Vivo and Translational Approach. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A58-A58	1.6	
45	Impact of early-stage HIV transmission on treatment as prevention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 15867-8	11.5	14
44	Biomedical prevention: state of the science. <i>Clinical Infectious Diseases</i> , 2014 , 59 Suppl 1, S41-6	11.6	7
43	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. <i>Cell</i> , 2014 , 158, 481-91	36.2	213
42	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014 , 514, 455-61	50.4	576
41	Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. <i>Lancet, The</i> , 2013 , 382, 1515-24	40	177
40	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013 , 496, 469-76	50.4	759
39	Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). <i>Journal of Infectious Diseases</i> , 2013 , 208, 1624-8	7	60
38	HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. <i>PLoS ONE</i> , 2013 , 8, e71557	3.7	17
37	HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies?. <i>PLoS Medicine</i> , 2012 , 9, e1001232	11.6	81
36	Detection of acute HIV infection: a field evaluation of the determine [®] HIV-1/2 Ag/Ab combo test. <i>Journal of Infectious Diseases</i> , 2012 , 205, 528-34	7	95

35	Prevention of HIV-1 infection with early antiretroviral therapy. <i>New England Journal of Medicine</i> , 2011 , 365, 493-505	59.2	5157
34	The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. <i>Lancet, The</i> , 2011 , 378, 256-68	4.0	251
33	HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, 437-42	3.1	124
32	Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1918-26	7	88
31	The detection of acute HIV infection. <i>Journal of Infectious Diseases</i> , 2010 , 202 Suppl 2, S270-7	7	188
30	Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. <i>PLoS Computational Biology</i> , 2010 , 6, e1000955	5	71
29	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1273-89	16.6	600
28	Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. <i>Journal of Virology</i> , 2008 , 82, 12449-63	6.6	452
27	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 7552-7	11.5	1472
26	Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. <i>PLoS Medicine</i> , 2008 , 5, e30	11.6	15
25	Prevention of the sexual transmission of HIV-1: preparing for success. <i>Journal of the International AIDS Society</i> , 2008 , 11, 4	5.4	12
24	Preventing sexual transmission of HIV. <i>Clinical Infectious Diseases</i> , 2007 , 45 Suppl 4, S287-92	11.6	37
23	Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. <i>Aids</i> , 2007 , 21, 2237-42	3.5	71
22	Thomas Parran Award Lecture: transmission and prevention of transmission of HIV-1. <i>Sexually Transmitted Diseases</i> , 2006 , 33, 338-41	2.4	8
21	Amplified transmission of HIV-1: missing link in the HIV pandemic. <i>Transactions of the American Clinical and Climatological Association</i> , 2006 , 117, 213-24; discussion 225	0.9	6
20	Frequent detection of acute primary HIV infection in men in Malawi. <i>Aids</i> , 2004 , 18, 517-24	3.5	101
19	Sexually transmitted infections and associated socio-demographic and behavioural factors in women seeking primary care suggest Madagascar's vulnerability to rapid HIV spread. <i>Tropical Medicine and International Health</i> , 2001 , 6, 202-11	2.3	37
18	Preventing transmission of HIV: a biological and medical perspective. <i>AIDS Patient Care and STDs</i> , 2001 , 15, 427-9	5.8	2

17	Antigenic variation of gonococcal pilin expression in vivo: analysis of the strain FA1090 pilin repertoire and identification of the pilS gene copies recombining with pilE during experimental human infection. <i>Microbiology (United Kingdom)</i> , 2001 , 147, 839-849	2.9	53
16	An epidemiological evaluation of the use of microbiological tools for identifying gonorrhoea infection networks. <i>International Journal of STD and AIDS</i> , 1999 , 10, 316-23	1.4	5
15	Chancroid, primary syphilis, genital herpes, and lymphogranuloma venereum in Antananarivo, Madagascar. <i>Journal of Infectious Diseases</i> , 1999 , 180, 1382-5	7	62
14	The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. <i>Molecular Microbiology</i> , 1998 , 27, 611-6	4.1	184
13	Free radicals and phagocytic cells. <i>FASEB Journal</i> , 1995 , 9, 200-9	0.9	385
12	Effects of H ₂ O ₂ -producing lactobacilli on <i>Neisseria gonorrhoeae</i> growth and catalase activity. <i>Journal of Infectious Diseases</i> , 1994 , 170, 1209-15	7	80
11	Application of spin trapping to human phagocytic cells: insight into conditions for formation and limitation of hydroxyl radical. <i>Free Radical Research Communications</i> , 1991 , 12-13 Pt 1, 17-25		7
10	Application of spin traps to biological systems. <i>Free Radical Research Communications</i> , 1990 , 9, 187-95		24
9	The role of hydroxyl radical in chromosomal and plasmid damage in <i>Neisseria gonorrhoeae</i> in vivo. <i>Free Radical Research Communications</i> , 1989 , 7, 83-7		7
8	Detection of free radicals as a consequence of dog tracheal epithelial cellular xenobiotic metabolism. <i>Xenobiotica</i> , 1989 , 19, 635-43	2	11
7	Calcium chelator Quin 2 prevents hydrogen-peroxide-induced DNA breakage and cytotoxicity. <i>FEBS Journal</i> , 1989 , 182, 209-12		132
6	Bacterial adaptation to oxidative stress: implications for pathogenesis and interaction with phagocytic cells. <i>FASEB Journal</i> , 1989 , 3, 2574-82	0.9	180
5	Metabolic responses of <i>Neisseria gonorrhoeae</i> to human serum and myeloid cells. Adaptation to host defenses?. <i>Antonie Van Leeuwenhoek</i> , 1987 , 53, 545-50	2.1	1
4	Phagocytic cells in periodontal defense. Periodontal status of patients with chronic granulomatous disease of childhood. <i>Journal of Periodontology</i> , 1985 , 56, 611-7	4.6	41
3	The great cephalosporin wars. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1984 , 3, 177-9	5.3	
2	Automated cytochemical staining and inflammation. Further assessment of the "left shift". <i>American Journal of Clinical Pathology</i> , 1982 , 78, 445-9	1.9	13
1	Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021		4